Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, United States.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, United States.
Leuk Res. 2021 Jul;106:106569. doi: 10.1016/j.leukres.2021.106569. Epub 2021 Mar 31.
Acute Promyelocytic Leukemia (APL) is a unique subtype of acute myeloid leukemia that is highly responsive to minimally myelosuppressive therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). We and others have observed a higher than expected incidence of herpes zoster reactivation in APL patients treated with ATO. Memorial Sloan Kettering Cancer Center (MSKCC) has been using ATO since 1997 in all relapsed APL patients, and more recently has included it in our front-line APL regimens. Here we present a retrospective analysis of the factors contributing to herpes zoster reactivation among APL patients.
急性早幼粒细胞白血病(APL)是一种独特的急性髓细胞白血病亚型,对全反式维甲酸(ATRA)和三氧化二砷(ATO)的低强度骨髓抑制治疗有高度反应性。我们和其他人观察到,在用 ATO 治疗的 APL 患者中,带状疱疹再激活的发生率高于预期。纪念斯隆凯特琳癌症中心(MSKCC)自 1997 年以来在所有复发性 APL 患者中使用 ATO,最近已将其纳入我们的一线 APL 治疗方案。在这里,我们对导致 APL 患者带状疱疹再激活的因素进行了回顾性分析。